Cargando…

Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma

Lymphoma is the sixth most common type of cancer worldwide. Under the current treatment standards, patients with lymphoma often fail to respond to treatment or relapse early and require further therapy. Hence, novel therapeutic strategies need to be explored and our understanding of the molecular un...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tiantian, Xu-Monette, Zijun Y., Yu, Li, Li, Yong, Young, Ken H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676406/
https://www.ncbi.nlm.nih.gov/pubmed/38007476
http://dx.doi.org/10.1038/s41419-023-06295-w
_version_ 1785149935544434688
author Yu, Tiantian
Xu-Monette, Zijun Y.
Yu, Li
Li, Yong
Young, Ken H.
author_facet Yu, Tiantian
Xu-Monette, Zijun Y.
Yu, Li
Li, Yong
Young, Ken H.
author_sort Yu, Tiantian
collection PubMed
description Lymphoma is the sixth most common type of cancer worldwide. Under the current treatment standards, patients with lymphoma often fail to respond to treatment or relapse early and require further therapy. Hence, novel therapeutic strategies need to be explored and our understanding of the molecular underpinnings of lymphomas should be expanded. Ferroptosis, a non-apoptotic regulated cell death, is characterized by increased reactive oxygen species and lipid peroxidation due to metabolic dysfunction. Excessive or lack of ferroptosis has been implicated in tumor development. Current preclinical evidences suggest that ferroptosis participates in tumorigenesis, progression, and drug resistance of lymphoma, identifying a potential biomarker and an attractive molecular target. Our review summarizes the core mechanisms and regulatory networks of ferroptosis and discusses existing evidences of ferroptosis induction for the treatment of lymphoma, with intent to provide a framework for understanding the role of ferroptosis in lymphomagenesis and a new perspective of lymphoma treatment.
format Online
Article
Text
id pubmed-10676406
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106764062023-11-25 Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma Yu, Tiantian Xu-Monette, Zijun Y. Yu, Li Li, Yong Young, Ken H. Cell Death Dis Review Article Lymphoma is the sixth most common type of cancer worldwide. Under the current treatment standards, patients with lymphoma often fail to respond to treatment or relapse early and require further therapy. Hence, novel therapeutic strategies need to be explored and our understanding of the molecular underpinnings of lymphomas should be expanded. Ferroptosis, a non-apoptotic regulated cell death, is characterized by increased reactive oxygen species and lipid peroxidation due to metabolic dysfunction. Excessive or lack of ferroptosis has been implicated in tumor development. Current preclinical evidences suggest that ferroptosis participates in tumorigenesis, progression, and drug resistance of lymphoma, identifying a potential biomarker and an attractive molecular target. Our review summarizes the core mechanisms and regulatory networks of ferroptosis and discusses existing evidences of ferroptosis induction for the treatment of lymphoma, with intent to provide a framework for understanding the role of ferroptosis in lymphomagenesis and a new perspective of lymphoma treatment. Nature Publishing Group UK 2023-11-25 /pmc/articles/PMC10676406/ /pubmed/38007476 http://dx.doi.org/10.1038/s41419-023-06295-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Yu, Tiantian
Xu-Monette, Zijun Y.
Yu, Li
Li, Yong
Young, Ken H.
Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma
title Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma
title_full Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma
title_fullStr Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma
title_full_unstemmed Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma
title_short Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma
title_sort mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676406/
https://www.ncbi.nlm.nih.gov/pubmed/38007476
http://dx.doi.org/10.1038/s41419-023-06295-w
work_keys_str_mv AT yutiantian mechanismsofferroptosisandtargetedtherapeuticapproachesinlymphoma
AT xumonettezijuny mechanismsofferroptosisandtargetedtherapeuticapproachesinlymphoma
AT yuli mechanismsofferroptosisandtargetedtherapeuticapproachesinlymphoma
AT liyong mechanismsofferroptosisandtargetedtherapeuticapproachesinlymphoma
AT youngkenh mechanismsofferroptosisandtargetedtherapeuticapproachesinlymphoma